REMATIB 15 mg (Upadacitinib INN) (Upadacitinib Hemihydrate)

Upadacitinib Hemihydrate Composition: Each Extended-Release Tablet Contains Upadacitinib 15mg as Upadacitinib Hemihydrate. Indication: Rematib is a Janus Kinase (JAK) inhibitor indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to…